Truist analyst Michael Lewis raised the firm’s price target on American Healthcare REIT to $22 from $17 and keeps a Buy rating on the shares. The firm cites the company’s strong net operating income growth, which drove an earnings beat and a guidance raise in Q2, adding that the improving cost of equity and debt capital also improves American Healthcare’s potential growth prospects, the analyst tells investors in a research note. Even following the recent outperformance, the stock has the most attractive three- and five-year multiples in its healthcare REIT coverage, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AHR:
- American Healthcare REIT added to ‘US 1 List’ at BofA
- American Healthcare REIT price target raised to $22 from $17 at Morgan Stanley
- American Healthcare REIT price target raised to $27 from $19 at BofA
- American Healthcare REIT files ot sell 3.5M shares of common stock for holders
- American Healthcare REIT files automatic mixed securities shelf